What were the key takeaways from The Cooper Companies’s earnings call?

What is the market's earnings forecast for The Cooper Companies next quarter?

What is the revenue and EPS growth rate for The Cooper Companies year over year?

What is The Cooper Companies's latest dividend and current dividend yield?

What were the key takeaways from The Cooper Companies's earnings call?

Did The Cooper Companies beat or miss consensus estimates last quarter?

What guidance did The Cooper Companies's management provide for the next earnings period?

What does The Cooper Companies do and what are its main business segments?

- **MyDay Dominance**: Q4 daily SiHy growth 5%, with MyDay Energys and toric launches driving 37% MiSight growth. FY26 MyDay-led CooperVision guidance 4.5-5.5% vs. market 4-5%. 
- **Cash Flow Acceleration**: $2.2B+ 2026-28 FCF, up from $1.7B prior, via $50M/year savings and CapEx decline. 
- **Strategic Flexibility**: Board-endorsed review of separation, with $2B buyback plan and 2/3 FCF allocation to shares. 
- **APAC Recovery**: China e-commerce exit offsets 28% decline, with Japan MyDay/MiSight launches in Q2. 
- **Fertility Resilience**: FY26 low-single-digit growth, supported by Witness adoption and genomics tests.

**【CEO Summary Section】**
- Emphasized three strategic priorities: market share gains for CooperVision, earnings/cash flow growth, and capital returns. Highlighted MyDay's momentum, with Q4 revenue up 3.2% organically and 4.6% overall, driven by daily silicone hydrogel lenses. 
- Guided FY26 CooperVision growth of 4.5-5.5% organically, citing MyDay contract wins and launches in Japan and Europe. 
- Raised free cash flow target to $2.2B+ over 2026-28, driven by cost savings ($50M/year) and declining CapEx. 
- Announced strategic review, including potential separation of CooperVision and CooperSurgical, with Board support for exploring alternatives.

**【CFO Financial Commentary】**
- Q4 GAAP net income $420M, Non-GAAP EPS $1.15 (vs. $1.08 consensus). Free cash flow $150M, up 20% YoY. 
- FY26 guidance: $4.3B-$4.34B revenue, $4.45-$4.60 EPS. Operating margin expansion via expense leverage, offset by mix/tariff headwinds. 
- Share buybacks (2/3 of FCF) and debt paydown as top capital priorities. 
- FY26 free cash flow $575M-$625M, up 20% YoY, driven by lower CapEx and working capital gains.

**【Q&A Highlights】**
- **MyDay Momentum**: CEO confident in Q3/Q4 share gains, citing new U.S./Europe contracts. CFO noted daily SiHy mix pressure on gross margin but higher profit per patient. 
- **Strategic Review**: CEO reaffirmed no bias toward separation but open to unlocking value. CFO highlighted $50M/year savings from reorg. 
- **Market Dynamics**: 4-5% global contact lens market growth, with APAC e-commerce weakness offset by MyDay wins. 
- **Fertility Outlook**: FY26 low-single-digit growth, citing easier comps and genomics tech adoption. 
- **Free Cash Flow**: CFO detailed $2.2B+ target via declining CapEx, with FY27 CooperVision CapEx normalizing to 5% of revenue.

The Cooper Companies, Inc. (COO) Q4 2025 Earnings Call Transcript

- **Revenue resilience**: $1.06 billion Q3 revenue with 5.7% YoY growth, despite Clariti decline and APAC e-commerce challenges.
- **MyDAY transformation**: Double-digit growth, 30+ new private label contracts, and 300% trial lens increase, positioning for FY26 market outperformance.
- **Financial strength**: Non-GAAP EPS up 15%, free cash flow $165M, and $2B+ free cash flow target over 3 years.
- **FY26 outlook**: 2-4% Q4 organic growth, CooperVision to match/beat contact lens market with MyDAY, CooperSurgical recovery driven by Asia Pac fertility rebound.
- **Risks**: Clariti short-term headwinds, tariff pressures, and slow MyDAY revenue conversion from fittings.

**【CEO Summary Section】**
- Q3 consolidated revenues: $1.06 billion (5.7% YoY, 2% organic). Non-GAAP EPS: $1.10 (15% YoY growth). Free cash flow: $165 million.
- CooperVision: $718 million (6.3% YoY, 2.4% organic). Challenges: Clariti decline (global, especially APAC), e-commerce weakness in APAC, and MyDAY fitting activity impacting near-term revenue.
- MyDAY growth: Double-digit, with torics and multifocals leading. New launches in Europe and APAC. Clariti expected to recover with new product launches.
- CooperSurgical: $342 million (4.5% YoY, 2% organic). Fertility market softness offset by genomics/consumables growth. Surgical devices (e.g., obp Surgical) performed well.
- Q4 guidance: 2-4% organic growth for both segments. FY26 outlook: Outpace contact lens market with MyDAY momentum and CooperSurgical recovery.

**【CFO Financial Commentary】**
- Gross margin: 67.3% (up 70bps vs. prior quarter). Operating margin: 26.1%. Non-GAAP EPS: $1.10-$1.14 for Q4. Free cash flow: ~$100 million for Q4, full year ~$385 million.
- Tariff mitigation: $24 million impact, offset by cost management. FY2026 free cash flow target: $2 billion over 3 years. Share buybacks: $52 million in Q3, $164 million remaining.

**【Q&A Key Highlights】**
- **MyDAY vs. Clariti dynamics**: Clariti orders declined as optometrists prioritized MyDAY fittings. MyDAY trial activity strong but slow to convert to revenue. Clariti margins higher than MyDAY.
- **Market growth**: Contact lens market mid-single-digit growth (4% in Q1/Q2 2025). CooperVision lagging market in 2025 but expects to match/beat market in FY26 with MyDAY share gains.
- **Fertility recovery**: Asia Pac cycles expected to rebound in FY26. CooperSurgical to benefit from clinic investments post-delayed capital purchases.
- **Tariff and margin outlook**: Tariffs to pressure gross margins, but operating leverage and restructuring to drive margin expansion.
- **MiSight momentum**: EMEA growth strong, Japan launch in Q1 2026. Global sales target $100 million in FY25, with FY26 growth supported by new launches and promotions.


The Cooper Companies, Inc. (COO) Q3 2025 Earnings Call Transcript

- **Revenue Beat**: $1.002 billion (+6% YoY), driven by 10% growth in MyDay lenses and 35% surge in MySight myopia management.
- **Strategic Moves**: Free trial promotions for MySight expected to boost Q4 growth, despite Q3 headwinds. MyDay and Clarity launches in key markets.
- **Financial Strength**: Non-GAAP EPS $0.96 (+14%), free cash flow $18 million. Raised 2025 revenue guidance to $4.11-4.15 billion.
- **Risks**: 4% contact lens industry growth, fertility market softness in Asia Pac, $4 million tariff impact in 2025.
- **Margin Outlook**: Gross margin to improve in H2, free cash flow to reduce debt.

**【CEO Summary Section】**
- **Revenue Growth**: Consolidated revenue of $1.002 billion, up 6% year-over-year (7% organically). CooperVision grew 5% (7% organically), CooperSurgical grew 8% (7% organically). Non-GAAP EPS was $0.96, up 14% YoY.
- **Product Highlights**: MyDay daily lenses grew 10%, MySight myopia management reached $25 million (35% growth). Clarity lenses and Biofinity FRP showed strong performance. MySight free trial promotions expected to boost Q4 growth despite Q3 headwinds.
- **Market Trends**: Contact lens industry grew 4% in Q1, revised 2025 growth range to 4-6%. Fertility market softened in Asia Pac due to macroeconomic pressures, revised growth to low single-digits.
- **Guidance Update**: 2025 revenue guidance raised to $4.11-4.15 billion (5.5-6.5% growth), non-GAAP EPS to $4.05-4.11. Free cash flow expected $350-400 million, with debt reduction prioritized.

**【CFO Financial Commentary】**
- **Financial Performance**: GAAP net income $420 million, non-GAAP EPS $0.96. Gross margin 68%, operating margin 24.9%. R&D expenses up 21% due to new product development.
- **Cash Flow & Share Repurchase**: Free cash flow $18 million, CapEx $78 million. Repurchased 537,000 shares ($40.6 million), $215.8 million remaining under $1 billion plan.
- **Tariffs & FX Impact**: $4 million tariff impact in 2025, potential 3% EPS headwind in 2026. FX now 0.5% revenue headwind (down from 1.5%), 1% EPS headwind (down from 4%).

**【Q&A Highlights】**
- **Contact Lens Market**: FIT data strong, but channel inventory tightening. Q4 expected to outperform Q3 organically. MyDay and Clarity launches in Canada and Japan driving growth.
- **Fertility Challenges**: Asia Pac cycle decline and clinic capital delays. U.S. consumer caution despite long-term growth fundamentals. PARAGARD growth offsetting fertility softness.
- **Tariff Mitigation**: Evaluating price increases and supply chain adjustments. 2026 pre-mitigation impact $4 million, post-mitigation TBD.
- **Margin Outlook**: Gross margin to improve in H2, operating leverage from OpEx efficiency. Free cash flow to prioritize debt reduction and opportunistic buybacks.

The Cooper Companies, Inc. (COO) Q2 2025 Earnings Call Transcript

- **Record Q1 Performance**: $965M revenue (+4% YoY), $0.92 EPS beat, with CooperVision leading at $646M (+6% organic). 
- **MyDay Momentum**: Torics/multifocals up 10%, Energys launches imminent, and MyDay MySight in early planning stages. 
- **China Recovery**: Myopia management (+20%) offset core business softness; production ramp to support rebound. 
- **Financial Strength**: 68.7% gross margin, $101M free cash flow, and net debt reduction to $2.44B. 
- **Guidance Upside**: FY2025 EPS $3.94-$4.02 (+7%-9%), with FX weakness offering potential upside.

**【CEO Summary Section】**
- Q1 2025 revenue reached $965 million, up 4% YoY, driven by 6% organic growth in CooperVision and 2% in CooperSurgical. Non-GAAP EPS was $0.92, exceeding expectations.
- CooperVision highlights: MyDay torics and multifocals grew 10%, MySight myopia management grew 20%, and China faced softness due to channel inventory adjustments.
- CooperSurgical: Fertility segment saw 1% growth despite IT system upgrades, while surgical products grew 4% on strength in minimally invasive devices.
- Key initiatives: Expanded MyDay production capacity, accelerated international launches, and private label availability increases.

**【CFO Financial Commentary】**
- Gross margin improved to 68.7% (vs. 67.3% prior), driven by efficiency gains and product mix. Operating expenses rose 5% to 43.6% of revenue, with investments in R&D and commercial activities.
- Free cash flow was $101 million, with $89 million in CapEx. Net debt decreased to $2.44 billion, and the leverage ratio improved to 1.91x.
- Updated FY2025 guidance: Revenue $4.08-$4.16 billion (6%-8% organic growth), non-GAAP EPS $3.94-$4.02 (7%-9% growth). FX weakness could drive upside to EPS guidance.

**【Q&A Key Themes】**
- **MyDay Expansion**: CEO confirmed accelerated production enabling new market entries, with Q3/Q4 launches expected to drive growth. Private label business may outpace branded growth due to channel demand.
- **China Challenges**: Softness in core contact lens business, offset by myopia management growth. Management expects stabilization with improved product availability.
- **Competitive Dynamics**: PARAGARD growth (+12%) driven by new inserter design, despite competition from low-copper IUDs. Myopia management pipeline (MyDay MySight) positioned for FY26 launch.
- **Market Outlook**: Contact lens market forecast 5%-7% growth, with CooperVision targeting share gains via premium product innovation.


COO

COO fundamentals

Earnings Call

You can ask Aime